Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364884 | 0.91 | POLB (0.60) | POLBMAPTTHRBMTNR1AMTNR1B | |
| SCHEMBL7083251 | 0.91 | CYP2C9 (0.56) | POLBMAPTTHRBMTNR1AMTNR1B | |
| SCHEMBL7088180 | 0.89 | POLB (0.52) | POLBMAPTTHRBMTNR1AMTNR1B | |
| SCHEMBL7089095 | 0.87 | CYP2C9 (0.51) | POLBMAPTTHRBLMNACYP2C9 | |
| SCHEMBL8611898 | 0.87 | POLB (0.60) | POLBMAPTTHRBMTNR1AMTNR1B | |
| SCHEMBL11957636 | 0.85 | POLB (0.55) | POLBMAPTTHRBMTNR1AMTNR1B | |
| SCHEMBL6360882 | 0.85 | AR (0.61) | POLBMAPTTHRBMTNR1AMTNR1B | |
| SCHEMBL11629144 | 0.85 | POLB (0.55) | POLBMAPTTHRBMTNR1AMTNR1B | |
| SCHEMBL13991644 | 0.84 | MTNR1A (0.47) | POLBMAPTTHRBMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL11756567 | 0.84 | POLB (0.54) | POLBMAPTTHRBMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580416-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580416-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580416-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2016004272-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004272-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | SCHRODINGER, LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | SCHRODINGER, LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | SCHRODINGER, LLC | 2016-01-07 | — | — | US | disclosed |
| EP-0580121-B1 | Photosensitive polyfunctional aromatic diazo compounds and photosensitive compositions using the same | TOYO GOSEI KOGYO KK (JP) | 1998-04-08 | — | — | EP | disclosed |
| US-5589315-A | SHELF LIFE, SCREEN PRINTING | TOYO GOSEI KOGYO CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| US-5430130-A | Photosensitive polyfunctional aromatic diazo compounds useful in photosensitive compositions | TOYO GOSEI KOGYO CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| EP-0580121-A2 | Photosensitive polyfunctional aromatic diazo compounds and photosensitive compositions using the same | TOYO GOSEI KOGYO CO., LTD. (JP) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | POLB 1765/4885MAPT 4186/4885THRB 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.